FDA Approves Two First-in-Class Oral Antibiotics for Gonorrhea in 24-Hour Span

Dec 13, 2025 14:43 CST Updated 14:43

GSK

Pharmaceutical R&D Manufacturer

Innoviva

Small Molecule Drug Research, Development, and Production

Abstract:After Three Decades, Major Breakthrough in Gonorrhea Treatment. The U.S. FDA has approved two first-ever oral drugs for gonorrhea treatment within 24 hours—GSK's Blujepa and Innoviva's Nuzolvence. These two drugs offer new options for treating multidrug-resistant gonorrhea, potentially alleviating an urgent threat to global public health.

After 30 Years of Silence, Two New Drugs Approved in Quick Succession

On December 12, the FDA announced the approval of Innoviva's Nuzolvence (zoliflodacin) for the treatment of uncomplicated urogenital gonorrhea. This came less than 24 hours after GSK's Blujepa received approval for the same indication; this drug had already been approved in March this year for uncomplicated urinary tract infections.

Both drugs are approved for patients aged 12 years and older who are ineligible for, intolerant of, or unwilling to pursue first-line standard treatments. There are slight differences in weight requirements: Nuzolvence is approved for patients weighing at least 35 kg (77 lbs), while Blujepa requires patients to weigh no less than 99 lbs.

This密集 approval has broken the three-decade-long drought of new drugs in the field of gonorrhea treatment. According to statistics, more than 80 million people worldwide are infected with gonorrhea each year, and in 2023, over 600,000 cases were reported in the United States, making it the second most common sexually transmitted disease after chlamydia.

Antibiotic Resistance Crisis Spurs Innovation, Public-Private Partnerships Become Key

This approval comes at a time when antimicrobial resistance in gonorrhea is becoming increasingly severe. Both the World Health Organization and the U.S. Centers for Disease Control and Prevention have listed gonorrhea as a priority pathogen, recognizing it as an urgent public health threat. For a long time, the rapid development of resistance has far outpaced the speed of antibiotic development, leading to a continued reduction in clinical treatment options.

The development of Nuzolvence is a model of public-private partnership. The drug was initiated by the Global Antibiotic Research and Development Partnership (GARDP) and has entered Phase III clinical trials. This non-profit collaboration focuses on global health needs, expanding drug accessibility in high disease burden regions while safeguarding the long-term effectiveness of new drugs.

"This approval marks a major turning point in the treatment of multidrug-resistant gonorrhea, as the development of resistance has consistently outpaced antibiotic innovation," said Dr. Manica Balasegaram, Executive Director of GARDP.

Oral administration advantages highlighted, clinical trials cover high-burden areas

The phase III clinical trial results of Nuzolvence were published simultaneously in The Lancet. The data showed that its efficacy was non-inferior to the current standard treatment regimen — injectable ceftriaxone combined with oral azithromycin. More importantly, this oral medication does not require injection and is suitable for patients allergic to penicillin-class drugs, addressing two significant unmet clinical needs.

The trial covered 16 sites across five countries, including Belgium, the Netherlands, South Africa, Thailand, and the United States, which are regions with high incidences of gonorrhea, enrolling a total of 930 patients. This is the largest clinical trial for a new drug targeting the pathogens causing gonorrhea. Dr. Rossaphorn Kittiyaowamarn, the principal investigator at the Bangrak Sexually Transmitted Diseases Center in Thailand, pointed out that conducting trials in high-burden countries and populations is of great significance for introducing effective treatment options.

If gonorrhea is not treated in a timely or adequate manner, it may lead to infertility and other sexual and reproductive health issues. Innoviva CEO Pavel Raifeld emphasized that this approval is a key milestone for patients and the broader medical community, demonstrating the company’s R&D capabilities and the fruits of collaboration with the global scientific community.

Innoviva, formerly a patent licensing management company established in 1996, was renamed in 2016 and acquired two biopharmaceutical companies in 2022 to form a subsidiary focused on the commercialization of treatments for critical care and infectious diseases. The approval of Nuzolvence marked a significant achievement following its transformation.

Reference Source:https://www.fiercepharma.com/pharma/fda-endorses-another-gonorrhea-treatment-blessing-innovivas-nuzolvence

Scan the WeChat QR code to add.Medicine Space-TimeEditor

Please indicate: Name + Research Direction!